What You Should Know
- ECRI, a nonprofit patient safety organization, submitted formal recommendations to the House Energy and Commerce Subcommittee on Health in April 2026.
- The organization warns that many general wellness devices—measuring vitals like blood pressure and glucose—lack FDA oversight and clinical validation, creating “invisible” risks for users.
- ECRI raised concerns regarding the Digital Health Screeners Act of 2026, specifically citing the lack of mandatory reporting for non-regulated devices.
- Policy recommendations include creating a public-facing classification system to distinguish validated medical devices from wellness products.
- ECRI emphasized that transparency in Clinical Decision Support (CDS) tools is vital to prevent automation bias among clinicians.
The digital health market is expanding at a rate that currently outpaces federal safety protections. In a statement provided for the congressional hearing, Healthier America: Legislative Proposals to Improve Public Health, ECRI cautioned lawmakers that current regulatory gaps could lead to significant patient harm. The organization highlighted a dangerous lack of distinction between clinically validated medical devices and general wellness tools that estimate high-stakes physiologic parameters like oxygen saturation and electrocardiograms.
Dr. Scott Lucas, ECRI’s vice president of device safety, noted that users often cannot tell the difference between a device that has undergone rigorous FDA scrutiny and one that has not. This confusion leads to inappropriate clinical reliance on unvalidated data, made worse by the fact that wellness devices are not subject to mandatory reporting or standardized post-market surveillance.
The Transparency Crisis in Clinical Decision Support
Beyond consumer wearables, ECRI is sounding the alarm on the software used to assist physicians. While the FDA has issued guidance on Clinical Decision Support (CDS) tools, ECRI argues that enforceable transparency requirements are missing. Proposed legislative exemptions for certain CDS tools could further reduce oversight, potentially leaving clinicians in the dark about how recommendations are generated.
Without access to underlying algorithms or training data, ECRI warns that “automation bias” may take hold, causing providers to over-rely on technology at the expense of their own independent clinical judgment. To mitigate this, the organization is calling for mandatory validation of performance across diverse demographic groups to ensure that algorithmic bias does not worsen existing healthcare disparities.
Targeted Policy Measures for a Safer Future
To protect patients in this rapidly evolving landscape, ECRI urged Congress to adopt four critical pillars of oversight:
- Clear Classification: Implement a public-facing system to clearly identify validated medical products.
- Expanded Authority: Update oversight to account for the risks of inaccurate physiologic data, rather than just traditional physical or electrical hazards.
- Enforceable Standards: Require total transparency for all CDS tools used in direct clinical care.
- Demographic Validation: Mandate that devices be proven accurate across diverse patient populations to advance health equity.
ECRI specifically pointed to the history of pulse oximeters as an example of how technological inaccuracies can disproportionately impact underserved communities. As digital tools increasingly replace in-person care, ensuring their reliability across all demographics is no longer just a technical goal—it is a requirement for equitable healthcare.
